These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 12755664)

  • 1. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
    Taylor DM; Wright T; Libretto SE;
    J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis.
    Lucey JV; Libretto SE
    Ir J Med Sci; 2003; 172(4):195-201. PubMed ID: 15029989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
    Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
    Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.
    Kasper S; Jones M; Duchesne I;
    Int Clin Psychopharmacol; 2001 Jul; 16(4):189-96. PubMed ID: 11459332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost evaluation of risperidone compared with olanzapine.
    Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
    Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
    Zhao Z
    Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
    Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
    Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
    Procyshyn RM; Zerjav S
    Clin Ther; 1998; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
    Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
    Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [RODOS: risperidone olanzapine drug outcome studies in schizophrenia].
    De Beauchamp I; Giraud-Baro E; Gury C
    Encephale; 2002; 28 Spec No 2 Pt 2():S33-4. PubMed ID: 12587356
    [No Abstract]   [Full Text] [Related]  

  • 13. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
    Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
    Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications.
    Jerrell JM
    Schizophr Bull; 2002; 28(4):589-605. PubMed ID: 12795493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.
    Tunis SL; Faries DE; Nyhuis AW; Kinon BJ; Ascher-Svanum H; Aquila R
    Value Health; 2006; 9(2):77-89. PubMed ID: 16626411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study.
    Kasper S; Rosillon D; Duchesne I;
    Int Clin Psychopharmacol; 2001 Jul; 16(4):179-87. PubMed ID: 11459331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluations of olanzapine and risperidone.
    Shaw JW
    Am J Health Syst Pharm; 2002 Jul; 59(14):1366-75. PubMed ID: 12132564
    [No Abstract]   [Full Text] [Related]  

  • 19. Olanzapine and risperidone.
    Love RC; Kelly DL
    Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of cost, dosage and clinical preference for risperidone and olanzapine.
    Rabinowitz J; Lichtenberg P; Kaplan Z
    Schizophr Res; 2000 Dec; 46(2-3):91-6. PubMed ID: 11120420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.